Ladenburg Thalmann Financial Services’s Protalix BioTherapeutics PLX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,000	Closed	-$22K	–	5295
2018 Q3	$22K	Hold	3,000	–	–	﹤0.01%	3848
2018 Q2	$16K	Hold	3,000	–	–	﹤0.01%	3969
2018 Q1	$16K	Hold	3,000	–	–	﹤0.01%	3969
2017 Q4	$20K	Hold	3,000	–	–	﹤0.01%	3807
2017 Q3	$17K	Hold	3,000	–	–	﹤0.01%	3781
2017 Q2	$25K	Hold	3,000	–	–	﹤0.01%	3471
2017 Q1	$41K	Buy	+3,000	New	+$27K	﹤0.01%	3059

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Ladenburg Thalmann Financial Services's PLX Position: Q4 2018 in Review

Ladenburg Thalmann Financial Services sold out of Protalix BioTherapeutics (PLX) in Q4 2018, closing a stake of 3,000 shares — an estimated $22K sold.

Ladenburg Thalmann Financial Services first reported a position in PLX in Q1 2017 and held it in 7 quarters. The position peaked at $41K in Q1 2017. 36 funds tracked by Wall St. Rank hold PLX as of Q4 2018.

Ladenburg Thalmann Financial Services reported no remaining Protalix BioTherapeutics position as of Q4 2018 after selling out during the quarter.
Ladenburg Thalmann Financial Services sold 3,000 Protalix BioTherapeutics shares in Q4 2018, an estimated $22K.
Ladenburg Thalmann Financial Services first reported a position in Protalix BioTherapeutics in Q1 2017 and held it in 7 quarters.
Ladenburg Thalmann Financial Services's Protalix BioTherapeutics position peaked at $41K in Q1 2017.
36 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2018.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2018, filed 14 Feb 2019.